JP2009530398A - 高コレステロール血症及びアテローム性動脈硬化症を治療するための方法及び組成物 - Google Patents

高コレステロール血症及びアテローム性動脈硬化症を治療するための方法及び組成物 Download PDF

Info

Publication number
JP2009530398A
JP2009530398A JP2009501575A JP2009501575A JP2009530398A JP 2009530398 A JP2009530398 A JP 2009530398A JP 2009501575 A JP2009501575 A JP 2009501575A JP 2009501575 A JP2009501575 A JP 2009501575A JP 2009530398 A JP2009530398 A JP 2009530398A
Authority
JP
Japan
Prior art keywords
compound
formula
atherosclerosis
hypercholesterolemia
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009501575A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009530398A5 (https=
Inventor
エス ホタミシュリギル グーカン
オズジャン ウムット
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard University filed Critical Harvard University
Publication of JP2009530398A publication Critical patent/JP2009530398A/ja
Publication of JP2009530398A5 publication Critical patent/JP2009530398A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2009501575A 2006-03-22 2007-03-22 高コレステロール血症及びアテローム性動脈硬化症を治療するための方法及び組成物 Pending JP2009530398A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78515606P 2006-03-22 2006-03-22
PCT/US2007/007225 WO2007111992A2 (en) 2006-03-22 2007-03-22 Methods and compositions for treating hypercholesterolemia and atherosclerosis

Publications (2)

Publication Number Publication Date
JP2009530398A true JP2009530398A (ja) 2009-08-27
JP2009530398A5 JP2009530398A5 (https=) 2010-05-13

Family

ID=38541674

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009501575A Pending JP2009530398A (ja) 2006-03-22 2007-03-22 高コレステロール血症及びアテローム性動脈硬化症を治療するための方法及び組成物

Country Status (7)

Country Link
US (1) US20090312297A1 (https=)
EP (1) EP2001484A4 (https=)
JP (1) JP2009530398A (https=)
CN (1) CN101534641A (https=)
AU (1) AU2007230989A1 (https=)
CA (1) CA2679608A1 (https=)
WO (1) WO2007111992A2 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009078977A (ja) * 2007-09-25 2009-04-16 Japan Health Science Foundation 心筋の小胞体ストレス抑制剤
KR101555945B1 (ko) * 2014-11-27 2015-09-25 부산대학교 산학협력단 Ｔｕｄｃａ를 이용한 줄기세포 생물작용 활성 증가, 및 이를 포함하는 줄기세포 치료 보조제
JP2015193581A (ja) * 2014-03-20 2015-11-05 株式会社ファンケル 新規ステロール系化合物およびこれを含有するコレステロール吸収阻害剤
JP2018505889A (ja) * 2015-02-06 2018-03-01 ロンザ インコーポレイテッド アテローム形成を治療するためのシステムおよび方法

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080139520A1 (en) * 2006-08-22 2008-06-12 Jain Mahendra K Altering cholesterol and fat uptake by novel allosteric inhibitors of pancreatic phospholipase A2
KR101064937B1 (ko) * 2009-06-16 2011-09-15 박상규 타우로우루소데옥시콜릭산 또는 그의 염을 포함하는 혈관재협착 예방 또는 치료용 약학 조성물
EP2599481A1 (en) * 2011-11-30 2013-06-05 Lunamed AG 4-phenylbutyric acid for the treatment or prevention of various diseases
US9872865B2 (en) 2013-03-24 2018-01-23 Amylyx Pharmaceuticals Inc. Compositions for improving cell viability and methods of use thereof
US20160051567A1 (en) * 2013-03-27 2016-02-25 Metselex, Inc. Prevention and treatment of kidney damage
CN103919787A (zh) * 2014-04-17 2014-07-16 厦门大学 牛磺熊脱氧胆酸及其可接受的盐的制药用途
CN106794165A (zh) 2014-10-15 2017-05-31 伯克和博耶纽约 单不饱和脂肪酸组合物和治疗动脉粥样硬化的应用
EA036404B1 (ru) 2015-02-06 2020-11-06 Интерсепт Фармасьютикалз, Инк. Фармацевтические композиции для комбинированной терапии
HK1257556A1 (zh) * 2016-02-26 2019-10-25 耀石治疗公司 对正接受降脂疗法的纯合型家族性高胆固醇血症患者的治疗
CA3076235C (en) * 2017-10-02 2022-06-21 The Procter & Gamble Company Methods for inhibiting conversion of choline to trimethylamine (tma)
CN110279702B (zh) * 2019-07-18 2022-09-02 西安交通大学医学院第一附属医院 胆汁酸衍生物在防治动脉粥样硬化药物中的应用
CN110559303B (zh) * 2019-09-24 2023-06-02 江西天元药业有限公司 降血脂预防治疗心脑血管病和动脉粥样硬化的精制熊胆粉
US11583542B2 (en) 2019-12-16 2023-02-21 Amylyx Pharmaceuticals, Inc. Compositions of bile acids and phenylbutyrate compounds
KR102686453B1 (ko) * 2021-08-18 2024-07-17 전북대학교산학협력단 TUDCA 코팅된 나노입자 및 이를 포함하는 p-셀렉틴 리간드, p-셀렉틴 과발현 질병 치료용 조성물 및 진단용 영상 조영제
US12138272B2 (en) 2022-05-12 2024-11-12 Amylyx Pharmaceuticals, Inc. Methods and compositions for treating amyotrophic lateral sclerosis
WO2025054199A1 (en) * 2023-09-05 2025-03-13 Amylyx Pharmaceuticals, Inc. Compositions and methods for treating subjects with hepatic impairment

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63145232A (ja) * 1986-11-28 1988-06-17 ギファルメックス・エッセ・ピ・ア コレステロール代謝変化治療用薬剤

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL68769A (en) * 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
US5846964A (en) * 1993-07-19 1998-12-08 Tokyo Tanabe Company Limited Hepatitis C virus proliferation inhibitor
US6270954B1 (en) * 1996-04-10 2001-08-07 The Regents Of The University Of California Correction of genetic defects using chemical chaperones
WO1999026657A1 (en) * 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
KR20050103185A (ko) * 2002-11-07 2005-10-27 리전츠 오브 더 유니버스티 오브 미네소타 출혈과 관련된 신경계 손상의 치료 방법
WO2006069371A1 (en) * 2004-12-22 2006-06-29 Baylor College Of Medicine A method of plasma lipidation to prevent, inhibit and/or reverse atherosclerosis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63145232A (ja) * 1986-11-28 1988-06-17 ギファルメックス・エッセ・ピ・ア コレステロール代謝変化治療用薬剤

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6012051257; ＳＯＮＧ，Ｃ．　ｅｔ　ａｌ: 'Ｓｅｌｅｃｔｉｖｅ　ａｃｔｉｖａｔｉｏｎ　ｏｆ　ｌｉｖｅｒ　Ｘ　ｒｅｃｅｐｔｏｒ　ａｌｐｈａ　ｂｙ　６alpha-ｈｙｄｒｏｘｙ　ｂｉｌｅ　ａｃｉｄｓ　ａｎｄ　ａｎａｌｏｇｓ' Ｓｔｅｒｏｉｄｓ Ｖｏｌ．６５，　Ｎｏ．８, 2000, ｐ．４２３-４２７ *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009078977A (ja) * 2007-09-25 2009-04-16 Japan Health Science Foundation 心筋の小胞体ストレス抑制剤
JP2015193581A (ja) * 2014-03-20 2015-11-05 株式会社ファンケル 新規ステロール系化合物およびこれを含有するコレステロール吸収阻害剤
KR101555945B1 (ko) * 2014-11-27 2015-09-25 부산대학교 산학협력단 Ｔｕｄｃａ를 이용한 줄기세포 생물작용 활성 증가, 및 이를 포함하는 줄기세포 치료 보조제
US9896662B2 (en) 2014-11-27 2018-02-20 Pusan National University Industry-University Cooperation Foundation Process for enhancing stem cell bioactivity using tauroursodeoxycholic acid
JP2018505889A (ja) * 2015-02-06 2018-03-01 ロンザ インコーポレイテッド アテローム形成を治療するためのシステムおよび方法

Also Published As

Publication number Publication date
US20090312297A1 (en) 2009-12-17
EP2001484A2 (en) 2008-12-17
CN101534641A (zh) 2009-09-16
EP2001484A4 (en) 2010-04-21
AU2007230989A1 (en) 2007-10-04
WO2007111992A2 (en) 2007-10-04
WO2007111992A3 (en) 2008-11-06
CA2679608A1 (en) 2007-10-04

Similar Documents

Publication Publication Date Title
JP2009530398A (ja) 高コレステロール血症及びアテローム性動脈硬化症を治療するための方法及び組成物
US11141399B2 (en) Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9814733B2 (en) Compositions comprising EPA and obeticholic acid and methods of use thereof
US20060073213A1 (en) Reducing ER stress in the treatment of obesity and diabetes
US20100075894A1 (en) Reducing er stress in the treatment of obesity and diabetes
EP1680099A2 (en) Hdl-boosting combination therapy complexes
CA3212583A1 (en) Compositions having improved bioavailability of therapeutics
CA3101274A1 (en) Use of neutrophil elastase inhibitors in liver disease
ES3026786T3 (en) Pemafibrate in combination with a sglt2 inhibitor for the prophylactic or therapeutic treatment of liver diseases nonalcoholic fatty liver disease
US20240382512A1 (en) Treatment of Immune-Related Disorders, Kidney Disorders, Liver Disorders, Hemolytic Disorders, and Oxidative Stress-Associated Disorders Using NRH, NARH and Reduced Derivatives Thereof
JP6878596B2 (ja) Ｆｘｒアゴニストの組合せ
JP2019518022A (ja) 肝内胆汁うっ滞性疾患の処置
JP2020516622A (ja) ゲムカベン、薬学的に許容されるその塩、その組成物、およびその使用方法
JP5341749B2 (ja) 脂肪肝又は非アルコール性脂肪性肝炎の予防及び／又は治療のための医薬
AU2006304689A1 (en) Compositions for lowering serum cholesterol and/or triglycerides
WO2013169648A1 (en) Pharmaceutical combinations comprising a dgat1 inhibtor and a triglyceride lowering drug
JPWO2005074909A1 (ja) 併用医薬
JP2008522972A (ja) 脂肪酸エステルを有する安定性フェノフィブラート組成物
JP7596548B2 (ja) 胆管症の治療
EP3870169A1 (en) Lipoxin a4 analogs and uses thereof
CN105307653A (zh) 血脂异常症治疗剂
ES2359910T3 (es) Composición medicinal para inhibir la expresión de atp-citrato liasa y su uso.
BALLI NEXT-GENERATION ANTIHYPERLIPIDEMIC DRUGS
WO2010083279A2 (en) Methods for treating disorders associated with hyperlipidemia in a mammal

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100323

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100323

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121002

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121219

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121227

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130604